Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 24997998)

1.

Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND.

Mol Cell Proteomics. 2014 Oct;13(10):2618-31. doi: 10.1074/mcp.M114.040428. Epub 2014 Jul 5.

PMID:
24997998
2.

Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.

Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A.

Cancer Res. 2009 Oct 1;69(19):7548-56. doi: 10.1158/0008-5472.CAN-08-4783. Epub 2009 Sep 22.

3.

Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.

Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.

Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.

PMID:
23110505
4.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2004 May 1;10(9):3216-24.

5.

Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.

Mukherjee J, DeSouza LV, Micallef J, Karim Z, Croul S, Siu KW, Guha A.

Cancer Res. 2009 Nov 15;69(22):8545-54. doi: 10.1158/0008-5472.CAN-09-1778. Epub 2009 Nov 10.

6.

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.

Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F.

Mol Cancer. 2013 Apr 25;12:31. doi: 10.1186/1476-4598-12-31.

7.

Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.

Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN, White FM.

Mol Cell Proteomics. 2012 Dec;11(12):1724-40. doi: 10.1074/mcp.M112.019984. Epub 2012 Sep 10.

8.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS.

Cancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18.

9.

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ.

Cancer Res. 2009 Mar 15;69(6):2540-9. doi: 10.1158/0008-5472.CAN-08-1547. Epub 2009 Mar 10.

10.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

11.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

12.

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J.

J Neurooncol. 2008 Oct;90(1):9-17. doi: 10.1007/s11060-008-9627-0. Epub 2008 Jun 20.

PMID:
18566746
13.

The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.

Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.

J Neurooncol. 2011 May;102(3):353-66. doi: 10.1007/s11060-010-0345-z. Epub 2010 Oct 12.

14.

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.

Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72. Epub 2007 Jul 23.

15.

Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Stockhausen MT, Kristoffersen K, Stobbe L, Poulsen HS.

Cancer Biol Ther. 2014 Feb;15(2):216-24. doi: 10.4161/cbt.26736. Epub 2013 Nov 1.

16.

Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.

Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F.

J Exp Med. 2011 Dec 19;208(13):2657-73. doi: 10.1084/jem.20111102. Epub 2011 Dec 12.

18.

Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.

19.

Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K.

Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk